Nelson Dusetti: Is a la carte treatment possible for pancreatic adenocarcinoma?

Nelson Dusetti shared a post on LinkedIn:

“Next week, an important event will take place in Marseille: the EUS ENDO. We are excited to present “Is a la carte treatment possible for pancreatic adenocarcinoma?” during the session What’s new in Pancreatic Cancer? at 08:30.

The 8th EUS-ENDO Congress promises to be an exciting event for endoscopy experts. Global leaders will present the latest advancements in ERCP, ESD, and therapeutic EUS through live demonstrations.

The exhibition will feature cutting-edge scopes and accessories, with a focus on the synergy between EUS and ERCP in treating biliopancreatic diseases, along with innovative techniques like radiofrequency ablation and cholangio-pancreatoscopy.

With 250 participants expected, this congress offers clinicians a unique opportunity to learn from top experts and explore the latest technologies shaping the future of endoscopy.”

Source: Nelson Dusetti/LinkedIn

Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.